Anti-Cancer/ Oncology API Products
Explorar Anti-Cáncer / Oncologico Products
Acetato De Abiraterona
Anti-Cáncer / Oncologico
Adagrasib
Anti-Cáncer / Oncologico
Apalutamide (Amorphous & Form B)
Anti-Cáncer / Oncologico
Azacitidina
Anti-Cáncer / Oncologico
Clorhidrato De Bendamustina
Anti-Cáncer / Oncologico
Bortezomib
Anti-Cáncer / Oncologico
Cabazitaxel
Anti-Cáncer / Oncologico
Cabozantinib HCl
Anti-Cáncer / Oncologico
Cabozantinib S-Malate
Anti-Cáncer / Oncologico
Capecitabina
Anti-Cáncer / Oncologico
Carfilzomib
Anti-Cáncer / Oncologico
Darolutamide
Anti-Cáncer / Oncologico
Dasatinib
Anti-Cáncer / Oncologico
Decitabina
Anti-Cáncer / Oncologico
Deucravacitinib
Anti-Cáncer / Oncologico
Enzalutamida
Anti-Cáncer / Oncologico
Mesilato De Eribulina
Anti-Cáncer / Oncologico
Fosaprepitante
Anti-Cáncer / Oncologico
Fruquintinib
Anti-Cáncer / Oncologico
Gemcitabine Hydrochloride
Anti-Cáncer / Oncologico
Granisteron
Anti-Cáncer / Oncologico
Lenalidomida
Anti-Cáncer / Oncologico
Lenvatinib Mesylate (MIBK Solvate)
Anti-Cáncer / Oncologico
Lenvatinib Mesylate (Form-C)
Anti-Cáncer / Oncologico
Lomustina
Anti-Cáncer / Oncologico
Midostaurina
Anti-Cáncer / Oncologico
Nilotinib Clorhidrato
Anti-Cáncer / Oncologico
Niraparib Tosylate
Anti-Cáncer / Oncologico
Palbociclib
Anti-Cáncer / Oncologico
Pazopanib
Anti-Cáncer / Oncologico
Pemetrexed Disodium (Heptahidrato)
Anti-Cáncer / Oncologico
Pirtobrutinib
Anti-Cáncer / Oncologico
Pomalidomida
Anti-Cáncer / Oncologico
Relugolix
Anti-Cáncer / Oncologico
Ripretinib
Anti-Cáncer / Oncologico
Ritlecitinib
Anti-Cáncer / Oncologico
Tucatinib
Anti-Cáncer / Oncologico
Venetoclax
Anti-Cáncer / Oncologico
Zanubrutinib
Anti-Cáncer / Oncologico
Ácido Zoledrónico
Anti-Cáncer / Oncologico
Dr. Reddys Portfolio of Anti-cancer APIs
We manufacture our Anti-cancer APIs at cGMP API manufacturing facilities which are successfully inspected by international regulatory authorities such as the USFDA, EMEA, ANVISA, PMDA, and Health Canada.
Our team of process experts draws on their integrated understanding of IP, process development (API and formulation), and API manufacturing to ensure that by design, the process is lean, free from potential genotoxic impurities, and scalable to manufacture for early market entries. This is of particular importance to select the optimal synthesis route in the context of the IP situation. Other aspects are the solid-state forms and particle characteristics that are critical in formulation development.
We have incorporated sensitive and rigorous analytical methods to control the impurities at a specified level and extensively studied the flow properties, crystal size/shape, and morphology in accordance with future requirements. In addition, our APIs have been designed to address customized PSD requirements through size reduction and crystallization techniques, resulting in a high probability of successful formulation development.
USPs of our Anti-cancer APIs
- QbD approach for an efficient process & high-quality output
- Availability of APIs in various forms.
- cGMP API manufacturing facility - Successfully inspected by international regulatory authorities.
- GTIs & impurities are controlled below the TTC limit & ICH limits, respectively.
- Formulation dossier filed across all major markets.
- Regulatory filing available across the globe.
- Completely backward integrated on the Key starting materials to ensure uninterrupted supplies.
- Adequate capacity to meet the global demands.
- KSM suppliers with timely deliveries and adherence to stringent specifications.
- Process safety management guidelines are implemented to enable a sustainable product supply.
- IP-Compliant API that meets regulatory requirements.
Dr. Reddy, is well-positioned to meet the global demand for Anti-cancer/Oncology APIs. As for many of our APIs. the key starting materials (KW) are backward integrated today. We've also established strategic solid sourcing and logistics partnerships and work closely with our customers to successfully manage Me capacities of our manufacturing units ahead of launches.
To know more about our end-to-end solutions for Anti-cancer/Oncology APIs formulations and Dosage forms. Check out our board portfolio of Anti-cancer/Oncology APIs here (Link) (or) Contact us at [email protected].
Explorar other Therapeutic categories.
Category-Oncology FAQ
- The oncology API market aims to share and reshape the flow of the pharmaceutical industry's demand.
- The global oncology API market is expected to exhibit strong growth from 2022 to 2026.
- The cancer API Market is expected to reach USD 1,48,545.23 Million by 2030 at 7.10% CAGR during the forecast period 2022-2030.
Oncology drugs are therapeutics used to treat cancer, a group of diseases caused by uncontrolled growth and division of abnormal cells. Oncology drugs include a range of different types of medications, such as chemotherapy agents, targeted therapies, immunotherapies, and hormone therapies.
- Thalidomide Analogues
- Alkalyting agents
- Androgen receptors
- Folate Analog Metabolic
- Nucleoside
- Metabolic
- Microtubule
Alkylating agents - cross-linking of DNA strands, inhibiting DNA replication and RNA transcription. Some antimetabolites - Interfere with DNA or RNA synthesis. Alkaloids bind to tubulin and inhibit the formation of microtubules, causing metaphase arrest, and camptothecins inhibit topoisomerase. Others - induces cell death or differentiation.
The knock of the API sector is having a significant effect on the overall cancer API market growth. The Oncology API market has undergone immense changes due to supply chain disruption caused by COVID-19. COVID-19 has disrupted the pharmaceutical industry's production and supply chain.
The global oncology drugs market size was valued at 135.4 Billion in 2020 and is projected to reach 274.4 billion by 2030, registering a CAGR of 7.5% from 2021 to 2030.
Descargo de responsabilidad
Ninguna información en este sitio web, incluyendo cualquier referencia a cualquier producto o servicio, constituye una oferta de venta ni se interpretará como tal. Los productos protegidos por patentes válidas no se ofrecen ni suministran para uso comercial. Sin embargo, en ciertos casos, a discreción exclusiva de Dr. Reddy's y sujeto a los requisitos legales locales, las cantidades de investigación de dichos productos pueden ofrecerse para fines de presentaciones regulatorias según la Sección 107A de la Ley de Patentes de la India (exención de Bolar), donde existan dichas exenciones regulatorias. Los compradores deben realizar su propia evaluación del producto o servicio, incluyendo el escenario de patentes en sus respectivos mercados, y serán responsables de todas las responsabilidades relacionadas con las patentes. Dr. Reddy's renuncia a todas las garantías, expresas o implícitas, incluyendo, entre otras, las garantías de comerciabilidad, idoneidad para un propósito particular y no infracción.